For instance, Rosenstein et al., in a study including 457 pwMS, demonstrated that both IgM index and IgMIF serve as useful biomarkers in early relapsing MS, by predicting future disease activity over a 2-year follow-up period (outperforming OCMBs), and future disability [86]. Here, CD40LG is linked to myeloid sarcoma.